The Ministry of Health’s announcement of a National Orphan Drug Framework on 3 October 2012 was the first federal public acknowledgement of orphan drugs since the 1997 Drugs Directorate (DD) policy statement. The reform primarily announced an Orphan Drug Policy for Canada. This paper explains why the government decided to make this announcement now. Media and Parliamentary documents were analyzed for their use of symbols, numbers, and language in causal stories told by political actors. The initial story was that Canada’s population was too small and the cost too high for an orphan drug policy. Over the next fifteen years, a powerful interest group, the Canadian Organization for Rare Disorders (CORD), mobilized the rare disease community in...
Major Research Paper (Master's), Health, Faculty of Health, School of Health Policy and Management, ...
When the Scottish government recently launched a £21 million fund to provide patients with rare dise...
ABSTRACTThe effects of orphan drug policies raise serious concerns among payer organizations and lea...
The Ministry of Health’s announcement of a National Orphan Drug Framework on 3 October 2012 was the ...
Putting aside whether diseases that affect only small numbers of people ( rare diseases ) should be ...
Objectives: Unlike other high-income countries, Canada has no national policy for drugs treating rar...
While it is currently uncertain whether or not a Canadian orphan drug policy will be given further c...
In the context of Canada’s publicly funded universal health care system, access to potentially life-...
Decisions to reform pharmaceutical policy often involve trade-offs between competing social and comm...
Abstract : Rare diseases are debilitating conditions often leading to severe clinical manifestations...
Abstract Background In September 2003, the Canadian g...
Medical drugs of limited commercial interest (Orphan Drugs) represent a public policy dilemma. Debat...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
Cette contribution analyse les formes de militantisme politique et scientifique qui ont émergé autour...
Major Research Paper (Master's), Health, Faculty of Health, School of Health Policy and Management, ...
When the Scottish government recently launched a £21 million fund to provide patients with rare dise...
ABSTRACTThe effects of orphan drug policies raise serious concerns among payer organizations and lea...
The Ministry of Health’s announcement of a National Orphan Drug Framework on 3 October 2012 was the ...
Putting aside whether diseases that affect only small numbers of people ( rare diseases ) should be ...
Objectives: Unlike other high-income countries, Canada has no national policy for drugs treating rar...
While it is currently uncertain whether or not a Canadian orphan drug policy will be given further c...
In the context of Canada’s publicly funded universal health care system, access to potentially life-...
Decisions to reform pharmaceutical policy often involve trade-offs between competing social and comm...
Abstract : Rare diseases are debilitating conditions often leading to severe clinical manifestations...
Abstract Background In September 2003, the Canadian g...
Medical drugs of limited commercial interest (Orphan Drugs) represent a public policy dilemma. Debat...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
Cette contribution analyse les formes de militantisme politique et scientifique qui ont émergé autour...
Major Research Paper (Master's), Health, Faculty of Health, School of Health Policy and Management, ...
When the Scottish government recently launched a £21 million fund to provide patients with rare dise...
ABSTRACTThe effects of orphan drug policies raise serious concerns among payer organizations and lea...